J
Joseph A. Jakubowski
Researcher at Eli Lilly and Company
Publications - 198
Citations - 11147
Joseph A. Jakubowski is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Prasugrel & Clopidogrel. The author has an hindex of 49, co-authored 198 publications receiving 10627 citations.
Papers
More filters
Journal ArticleDOI
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Stephen D. Wiviott,Dietmar Trenk,Andrew L. Frelinger,Michelle L. O'Donoghue,Franz-Josef Neumann,Alan D. Michelson,Dominick J. Angiolillo,Hanoch Hod,Gilles Montalescot,Debra L. Miller,Joseph A. Jakubowski,Richard Cairns,Sabina A. Murphy,Carolyn H. McCabe,Elliott M. Antman,Eugene Braunwald +15 more
TL;DR: Among patients undergoing cardiac catheterization with planned percutaneous coronary intervention, loading with 60 mg prasugrel resulted in greater platelet inhibition than a 600-mg clopidogrel loading dose.
Journal ArticleDOI
A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
Dietmar Trenk,Gregg W. Stone,Meinrad Gawaz,Adnan Kastrati,Dominick J. Angiolillo,Ulrike Müller,Gert Richardt,Joseph A. Jakubowski,Franz-Josef Neumann +8 more
Journal ArticleDOI
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
John T. Brandt,Christopher D. Payne,Stephen D. Wiviott,Govinda Weerakkody,Nagy A. Farid,David S. Small,Joseph A. Jakubowski,Hideo Naganuma,Kenneth J. Winters +8 more
TL;DR: Prasugrel 60 mg LD results in more rapid, potent, and consistent inhibition of platelet function than clopidogrel 300 mg LD and is associated with lower plasma concentrations of its active metabolite.
Journal ArticleDOI
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
Tomas Jernberg,Christopher D. Payne,Kenneth J. Winters,Christelle Darstein,John T. Brandt,Joseph A. Jakubowski,Hideo Naganuma,Agneta Siegbahn,Lars Wallentin +8 more
TL;DR: In this population, prasugrel (40-60 mg LD and 10-15 mg MD) achieves greater IPA and a lower proportion of pharmacodynamic non-responders compared with the approved clopidogrel dosing.
Journal ArticleDOI
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
Gilles Montalescot,Leonardo Bolognese,Dariusz Dudek,Patrick Goldstein,Christian W. Hamm,Jean Francois Tanguay,Jurriën M. ten Berg,Debra L. Miller,Timothy M. Costigan,Jochen Goedicke,Johanne Silvain,Paolo Angioli,Jacek Legutko,Margit Niethammer,Zuzana Motovska,Joseph A. Jakubowski,Guillaume Cayla,Luigi Oltrona Visconti,Eric Vicaut,Petr Widimsky +19 more
TL;DR: Among patients with NSTE acute coronary syndromes who were scheduled to undergo catheterization, pretreatment with prasugrel did not reduce the rate of major ischemic events up to 30 days but increased the rates of major bleeding complications.